Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Nvidia Options Price in $280 Billion Earnings Swing 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Tesla Raises Cybertruck Prices by $5,000 in US 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
KPMG Australia Cuts 5% of Workforce Amid Scandal 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
California Seeks Paramount Divestitures in Warner Bros. Merger 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Add as a preferred source on Google
| Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) | |||||||
| Annual General Shareholders' Meeting of May 2, 2018 Shareholders' approval of the financial statements for 2017 Dividend of €3.03 per share payable as of May 15, 2018 Board Composition: renewals and appointment Paris (France) - May 2, 2018 - The Combined General Shareholders' Meeting of Sanofi was held today at the Palais des Congrès in Paris under the chairmanship of Serge Weinberg. All resolutions submitted to the vote were adopted by its shareholders. The shareholders approved, among other resolutions, the individual Company and consolidated financial statements for the year 2017. At the General Meeting, shareholders decided the distribution of a cash dividend in the amount of € 3.03 per share with payment as of May 15, 2018. The General Meeting also renewed as Directors Olivier Brandicourt, Patrick Kron and Christian Mulliez and approved the appointment of Emmanuel Babeau as independent Director, for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year 2021. Following the General Meeting, the new Board of Directors is still comprised of 16 members, of whom six are women and two are Directors representing employees. A large majority of the Board's Directors is independent: Serge Weinberg*, Chairman of the Board of Directors Olivier Brandicourt, Chief Executive Officer Laurent Attal Emmanuel Babeau* Bernard Charlès* Claudie Haigneré* Patrick Kron* Fabienne Lecorvaisier* Melanie Lee* Suet-Fern Lee* Christian Mulliez Marion Palme** Carole Piwnica* Christian Senectaire** Diane Souza* Thomas Südhof* The voting results will be available on the Company's website (www.sanofi.com/AGM2018) in the coming days. The audiocast of the Annual General Shareholder Meeting is available on the Company's website (www.sanofi.com/AGM2018). During the Board of Directors session following the meeting, the Board decided to review the composition of its Committees as follows: | |||||||
| Audit Committee | Strategic Committee | Compensation Committee | |||||
| Chairwoman/ Chairman | Fabienne Lecorvaisier* | Serge Weinberg* | Patrick Kron* | ||||
| Members | Emmanuel Babeau* Christian Mulliez Diane Souza* | Laurent Attal Olivier Brandicourt Patrick Kron* | Claudie Haigneré* Christian Mulliez Diane Souza* | ||||
| Appointments & Governance Committee | Scientific Committee | ||||||
| Chairman | Serge Weinberg* | Thomas Südhof* | |||||
| Members | Claudie Haigneré* Patrick Kron* | Laurent Attal Melanie Lee* Serge Weinberg* | |||||
| (* Independent Director) (** Director representing employees) | |||||||
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | |||||||
| Media Relations Contact Jack Cox Tel.: +33 (0)1 53 77 46 46 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] | ||||||
Attachment
